Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26715676
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb,
to Treat Ebola Virus Infection
#MMPMID26715676
Dowall SD
; Callan J
; Zeltina A
; Al-Abdulla I
; Strecker T
; Fehling SK
; Krähling V
; Bosworth A
; Rayner E
; Taylor I
; Charlton S
; Landon J
; Cameron I
; Hewson R
; Nasidi A
; Bowden TA
; Carroll MW
J Infect Dis
2016[Apr]; 213
(7
): 1124-33
PMID26715676
show ga
The highly glycosylated glycoprotein spike of Ebola virus (EBOV-GP1,2) is the
primary target of the humoral host response. Recombinant EBOV-GP ectodomain
(EBOV-GP1,2ecto) expressed in mammalian cells was used to immunize sheep and
elicited a robust immune response and produced high titers of high avidity
polyclonal antibodies. Investigation of the neutralizing activity of the ovine
antisera in vitro revealed that it neutralized EBOV. A pool of intact ovine
immunoglobulin G, herein termed EBOTAb, was prepared from the antisera and used
for an in vivo guinea pig study. When EBOTAb was delivered 6 hours after
challenge, all animals survived without experiencing fever or other clinical
manifestations. In a second series of guinea pig studies, the administration of
EBOTAb dosing was delayed for 48 or 72 hours after challenge, resulting in 100%
and 75% survival, respectively. These studies illustrate the usefulness of EBOTAb
in protecting against EBOV-induced disease.
|Animals
[MESH]
|Antibodies, Viral/economics/*therapeutic use
[MESH]
free
free
free
